Unless scientists develop new ways to stop the disease, the Alzheimer's Association projects that the number of people living with Alzheimer's disease will soar from 5 million to 13.8 million by 2050. Current medications do not treat Alzheimer's or stop it from progressing; they only temporarily lessen symptoms, such as memory loss and confusion.
Current Alzheimer's drugs aim to reduce the amyloid plaques—sticky deposits that build up in the brain--that are a visual trademark of the disease. The plaques are made of long fibers of a protein called Amyloid β, or Aβ. Recent studies, however, suggest that the real culprit behind Alzheimer's may be small Aβ clumps called oligomers that appear in the brain years before plaques develop.
AdvertisementFINDINGS In unraveling oligomers' molecular structure, UCLA scientists discovered that Aβ has a vastly different organization in oligomers than in amyloid plaques. Their finding could shed light on why Alzheimer's drugs designed to seek out amyloid plaques produce zero effect on oligomers.
P Finnish Government Gifts a Box of Condoms to William and Kate Research Finds Too Many 'Healing' Cells Delays Wound Healing M
You May Also Like